Literature DB >> 15332755

Varicella susceptibility among children and healthy adults in the United Arab Emirates.

S A Uduman1, A M Tahira, R Al-Wash, M A Usmani, A Bener.   

Abstract

The serological evidence of varicella zoster virus infection was determined among healthy individuals from infancy to 47 years of age living in this region. Of 648 people, 126 (19.4%) had no detectable antibody and were susceptible to infection. The overall adult seroprevalence rate was 81.3%. The rate among Emirati citizens increased with age; < 10 years, 45.8%; 11-20 years, 68.4%; 21-30 years, 89.5%; 31-40 years, 94.7%; and > 41 years, 88.9%. Adults from the Indian subcontinent and Philippines had variable prevalence rates and Sri Lankans living in the region were highly serosusceptible (35%). Because of the clinical impact of varicella in adult populations, vaccine prevention might be beneficial.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 15332755

Source DB:  PubMed          Journal:  East Mediterr Health J        ISSN: 1020-3397            Impact factor:   1.628


  4 in total

Review 1.  Epidemiology and factors influencing varicella infections in tropical countries including Sri Lanka.

Authors:  S W P Lakmini Daulagala; Faseeha Noordeen
Journal:  Virusdisease       Date:  2018-07-06

Review 2.  Varicella infection in the Middle East: Prevalence, complications, and vaccination.

Authors:  Mariam Al-Turab; Wassim Chehadeh
Journal:  J Res Med Sci       Date:  2018-04-26       Impact factor: 1.852

3.  Seroprevalence of measles, mumps, rubella, varicella-zoster and hepatitis A-C in Emirati medical students.

Authors:  Mohamud Sheek-Hussein; Rayhan Hashmey; Ahmed R Alsuwaidi; Fatima Al Maskari; Leena Amiri; Abdul-Kader Souid
Journal:  BMC Public Health       Date:  2012-12-05       Impact factor: 3.295

4.  The clinical and economic burden of varicella in the Middle East: a systematic literature review.

Authors:  Nawal Al Kaabi; Fatma Mohd Ali Sultan Al Olama; Mamoun Al Qaseer; Idris Al Ubaidani; Ener Cagri Dinleyici; Wail Ahmad Hayajneh; Abdul Rahman Bizri; Maysoon Loulou; Tidiane Ndao; Lara J Wolfson
Journal:  Hum Vaccin Immunother       Date:  2019-09-03       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.